Optimal stem cell source for allogeneic stem cell transplantation for hematological malignancies

Table 2 Randomized controlled trials comparing bone marrow and peripheral blood stem cell for matched related donor transplant

Ref.	No.ofpatients	Age of patients (yr)	Underlying diseases	Conditioning	Overall survival (BM vs PBSC)	Disease-free survival (BM vs PBSC)	Relapse (BM vs PBSC)	Transplant-related mortality (BM vs PBSC)	Acute graft-versus host disease (BM vs PBSC)	Chronic graft-versus host disease (BM vs PBSC)	Median time of neutrophil engraftment (d) (BM vs PBSC)	Median time of platelet engraftment (d) (BM vs PBSC)
[23,29]	56	7-59	Acute leukemias, CML, MDS, MM, NHL	Myeloablative1	48% vs 56%2 (2000 d)	50 vs 60%2 (2000 d)	NA	NA	23% vs 26%2 (grades 2-4)	61% vs 77%2 (extensive cGVHD)	18 vs 15a	18 vs 12b
[9]	39	22-51	Acute leukemias, CML, CLL, MDS, MM, NHL	Myeloablative1	63% vs 70%2 (2 yr)	NA	37% vs 0%a (2 yr)	32% vs 35%2	58% vs 68%2 (grades 1-4)	40% vs 44%2 (All cGVHD)	23 vs 17.5b	18 vs 11d
[25]	61	15-62	Acute leukemias, CML, MDS, PMF	Bu/Cy	73% vs 80%2 (4 yr)	55% vs 80%2 (4 yr)	30% vs 3%2	10% vs 17%2	10% vs 21%2 (grades 2-4)	27% vs 56%2 (All cGVHD)	23 vs 17d	21 vs 13d
[10,19]	101	Mean 37	Acute leukemias, CML	Myeloablative1	65% vs 67%2 (2 yr)	66% vs 67%2 (2 yr)	15% vs 6%2	21% vs 25%2	42% vs 44%2 (grades 2-4)	36% vs 65%b (All cGVHD) 17% vs 44%b (extensive cGVHD)	21 vs 153	21 vs 13d
[15-18]	329	19-58	Acute leukemias, CML, MDS	Myeloablative1	65% vs 65%2 (2 yr) 65% vs 58%2 (3 yr) 57% vs 49%2 (10 yr)	60% vs 56%2 (3 yr) 46% vs 42%2 (10 yr)	24% vs 20%2 (10 yr)	32% vs 24%2	42% vs 44%a (grades 2-4)	56% vs 74%b (All cGVHD) 19% vs 36%b (extensive cGVHD)	15 vs 12d	20 vs 15d
[12,13,20]	172	12-55	Acute leukemias, CML, CLL, MDS, MM, lymphomas	Myeloablative1	54% vs 66%2 (2 yr) 52% vs 55%2 (10 yr)	45% vs 65%a (2 yr) 40% vs 50%a (10 yr)	25% vs 14%a (2 yr) 32% vs 20%a (10 yr)	30% vs 21%2	57% vs 64%2 (grades 2-4)	52% vs 63%2 (extensive cGVHD)	21 vs 16d	19 vs 13d
[11]	227	19-64	AML, CML, MDS	Bu/Cy	60% vs 68%a (30 mo)	NA	9% vs 9%2	32% vs 21%2	44% vs 44%2 (grades 2-4)	69% vs 85%2 (All cGVHD) 30% vs 40%2 (extensive cGVHD)	23 vs 19d	22 vs 16d
[30]	110	15-62	Acute leukemias, MDS, MM, lymphomas	Myeloablative1	60% vs 34%a (4 yr)	NA	13% vs 18%2	28% vs 41%2	37% vs 52%2 (grades 2-4)	45% vs 61%2 (All cGVHD) 16% vs 28%2 (extensive cGVHD)	20 vs 15d	38 vs 25d
[14]	72	18-61	CML	Myeloablative1	72% vs 81%2 (3 yr)	65% vs 81%2 (3 yr)	15% vs 0%a (3 yr)	20% vs 19%2	49% vs 55%2 (grades 2-4)	50% vs 59%2 (extensive cGVHD)	22 vs 17a	21 vs 142

¹Different conditioning regimens;

²Not statistically significant;

^aP < 0.05,

^bP < 0.01,

^dP < 0.01. GVHD: Graft-versus-host disease; PBSC: Peripheral blood stem cell; HLA: Human leukocyte antigen; BM: Bone marrow; CML: Chronic myeloid leukemia; MDS: Myelodysplastic syndrome; MM: Multiple myeloma; NHL: Non-Hodgkin lymphoma; PMF: Primary myelofibrosis; AML: Acute myeloid leukemia; CLL: Chronic lymphocytic leukemia; Bu/Cy: Busulfan and cyclophosphamide; NA: Not available.